Phelan-McDermid syndrome (PMDS) is a complex neurodevelopmental disorder characterized by global developmental delay, severely impaired speech, intellectual disability, and an increased risk of autism spectrum disorders (ASDs) 1 . PMDS is caused by heterozygous deletions of chromosome 22q13.3. Among the genes in the deleted region is SHANK3, which encodes a protein in the postsynaptic density (PSD) 2, 3 . Rare mutations in SHANK3 have been associated with idiopathic ASDs [4] [5] [6] [7] , non-syndromic intellectual disability 8 , and schizophrenia
Phelan-McDermid syndrome (PMDS) is a complex neurodevelopmental disorder characterized by global developmental delay, severely impaired speech, intellectual disability, and an increased risk of autism spectrum disorders (ASDs) 1 . PMDS is caused by heterozygous deletions of chromosome 22q13.3. Among the genes in the deleted region is SHANK3, which encodes a protein in the postsynaptic density (PSD) 2, 3 . Rare mutations in SHANK3 have been associated with idiopathic ASDs [4] [5] [6] [7] , non-syndromic intellectual disability 8 , and schizophrenia 9 . Although SHANK3 is considered to be the most likely candidate gene for the neurological abnormalities in PMDS patients 10 , the cellular and molecular phenotypes associated with this syndrome in human neurons are unknown. We generated induced pluripotent stem (iPS) cells from individuals with PMDS and autism and used them to produce functional neurons. We show that PMDS neurons have reduced SHANK3 expression and major defects in excitatory, but not inhibitory, synaptic transmission. Excitatory synaptic transmission in PMDS neurons can be corrected by restoring SHANK3 expression or by treating neurons with insulin-like growth factor 1 (IGF1). IGF1 treatment promotes formation of mature excitatory synapses that lack SHANK3 but contain PSD95 and N-methyl-D-aspartate (NMDA) receptors with fast deactivation kinetics. Our findings provide direct evidence for a disruption in the ratio of cellular excitation and inhibition in PMDS neurons, and point to a molecular pathway that can be recruited to restore it.
To study cellular and molecular phenotypes associated with PMDS in humans, we generated six iPS cell lines from two patients with PMDS (Supplementary Table 1 ) that had deletions of approximately 1 megabases in chromosome 22 (Supplementary Fig. 1 and Supplementary Table 2 ) by using standard reprogramming techniques 11, 12 . As controls, we used iPS cell and human embryonic stem (ES) cell lines that were characterized in previous studies 12, 13 . Control and PMDS iPS cell lines had typical human ES-cell-like morphologies and expressed endogenous pluripotency marker proteins, but had suppressed the expression of the exogenous reprogramming factors, had normal karyotypes, and formed teratomas in vivo (Supplementary Fig. 2 and Supplementary Table 3 ). We differentiated control and PMDS iPS cells into neurons using a modified monolayer differentiation protocol ( Supplementary Fig. 3 ) and characterized the population of differentiated cells by quantitative PCR with reverse transcription (qRT-PCR) ( Supplementary Fig. 4 ). Similar populations of neuronal cells were found in cultures of control and PMDS neurons. Analysis of gene expression with multiplex single-cell qRT-PCR 13, 14 demonstrated that approximately 42% of cells expressed pan-neuronal markers, 15% expressed cortical layer markers, and only 2-5% of the cells expressed the synaptic markers SHANK1-SHANK3 ( Supplementary Fig. 5 ), indicating that only a small fraction of the cells were synaptically mature neurons. To enrich for mature forebrain neurons, we infected cells with enhanced green fluorescent protein (GFP) under the control of the CaMKIIa promoter (CaMKIIa-GFP) 15, 16 (Fig. 1a) . Single-cell profiling of GFP-expressing cells showed an approximate 12-fold enrichment in cells expressing SHANK1-SHANK3 (Fig. 1b) . These cells also expressed synaptic markers and genes typically found in the cortex and striatum, including TBR1, CUX1, SATB2, SOX5, FOXP1, CTIP2 (also known as BCL11B) and FOXP2 ( Supplementary Fig. 5 ) and were stained with antibodies recognizing MAP2 (,99%), TBR1 (,29%), CTIP2 (,66%), SATB2 (,42%), and c-aminobutyric acid (GABA) or GAD67 (,7.5%) ( Fig. 1c-h and Supplementary Fig. 6 ).
We next investigated the electrophysiological properties of control and PMDS neurons. Control and PMDS neurons expressing GFP had similar action potential characteristics, resting membrane potential and capacitance (Supplementary Table 4 ). PMDS neurons, however, had an increased input resistance and reduced amplitude and frequency of spontaneous synaptic events (Fig. 1i-j and Supplementary  Table 4) . A reduction in synaptic transmission in PMDS neurons could arise from differences in the number of neurons present in cultures of PMDS and control neurons. In fact, anti-MAP2 antibody staining revealed that our PMDS iPS cell lines produced slightly fewer neurons than controls ( Supplementary Fig. 7 ). To control for this difference in neuronal density and to study cells of both genotypes under identical experimental conditions, we infected control and PMDS neurons with either CaMKIIa-GFP or CaMKIIa-mKate2 and grew them together in the same dish (Fig. 2a) . Under these conditions, we found that the amplitude and frequency of spontaneous excitatory postsynaptic currents (EPSCs) recorded from PMDS neurons were significantly reduced relative to controls (Fig. 2b, c) , indicating that synaptic defects in PMDS neurons are postsynaptic and cell-autonomous. To determine if the changes in spontaneous EPSCs were also reflected in differences in evoked a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and NMDA-mediated synaptic responses, we measured currents induced by local field stimulation at 270 mV (AMPA-EPSCs) and 160 mV (NMDA-EPSCs). Smaller AMPA-and NMDA-EPSCs were measured in PMDS neurons in response to different stimulus intensities ( Fig. 2d-f ), indicating that both AMPA-and NMDA-mediated synaptic transmissions are significantly impaired.
To determine if inhibitory synaptic transmission was also altered in PMDS neurons, we recorded spontaneous and evoked inhibitory postsynaptic currents (IPSCs) (Fig. 2g-j ). There were no differences in IPSCs measured from co-cultured control and PMDS neurons. To determine the direction of the voltage shifts induced by IPSCs at this developmental stage, we measured voltage deflections induced by focal c-aminobutyric acid application ( Supplementary Fig. 8 ). Most control and PMDS neurons responded with hyperpolarizing shifts in membrane potential. These results indicate that the defects in PMDS neurons are limited to excitatory synaptic transmission and suggest that there is an alteration in the balance of cellular excitation and inhibition in PMDS neurons.
To gain insight into the mechanism underlying the impairment of excitatory synaptic transmission in PMDS neurons, we measured the expression levels of AMPA and NMDA receptors. PMDS neurons expressed significantly less GLUA1 and GLUN1 proteins (Fig. 3a) and generated significantly smaller currents in response to the focal application of either AMPA (Fig. 3b) or NMDA (Fig. 3c) . In contrast, the amplitude of c-aminobutyric-acid-evoked currents was similar for both control and PMDS neurons ( Supplementary Fig. 9 ), indicating that PMDS neurons express a decreased number of excitatory neurotransmitter receptors and normal levels of inhibitory receptors.
To determine whether the impairment in excitatory synaptic transmission in PMDS neurons is due to a reduced number of synapses, we immunostained co-cultured control and PMDS neurons with antibodies that recognize the presynaptic protein synapsin 1 (SYN1) and postsynaptic protein HOMER1 (Fig. 3d) . We observed a significant decrease in the number of puncta that were SYN1 1 ( Fig. 3e ) and HOMER1
1 SYN1 1 (Fig. 3f) in PMDS neurons as compared to controls, indicating that PMDS neurons have significantly fewer excitatory synapses than controls.
Although SHANK3 has been proposed to be primarily responsible for the neurological phenotype in PMDS patients, the vast majority of PMDS patients have 10-100 additional genes deleted. To determine whether the synaptic phenotypes in PMDS neurons are due to reduced SHANK3 expression, we measured the levels of SHANK3 messenger RNA and protein. Whereas MAP2, SHANK1 and SHANK2 were expressed at similar levels in control and PMDS neurons (Fig. 4a) , SHANK3 mRNA was significantly reduced in PMDS (Fig. 4a) . Western blot analysis showed a significant reduction in the expression of the longest SHANK3 protein isoform (Fig. 4b) , which was expressed primarily in neurons ( Supplementary Fig. 10 ). Immunostaining with anti-SHANK3 antibodies on co-cultured control and PMDS neurons also revealed a significantly reduced level of SHANK3 protein expression in PMDS neurons (Fig. 4c) , indicating that loss of a copy of SHANK3 in PMDS significantly downregulates the expression of the protein.
We next investigated whether we could reverse the synaptic phenotype in PMDS neurons by increasing SHANK3 expression. We infected PMDS neurons with a lentivirus containing the longest isoform of SHANK3 fused to EGFP ( Fig. 4d and Supplementary Fig. 11 ). SHANK3 expression in PMDS neurons restored both the amplitude and frequency of spontaneous EPSCs (Fig. 4e-g ). It also completely rescued evoked AMPA-and NMDA-EPSCs in 43% of recorded cells, and in CaMKIIa-GFP CaMKIIa-GFP TBR1 TBR1
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the remaining cells, it rescued only AMPA-EPSCs (Fig. 4h-j) . This indicates that loss of SHANK3 substantially contributes to the impaired excitatory synaptic transmission detected in PMDS neurons; however, it also suggests that SHANK3 may act differently on AMPA and NMDA receptors.
We next tested if we could restore synaptic deficits in PMDS neurons pharmacologically, using agents that have been previously reported to increase the level of SHANK3 expression or to increase synaptic transmission, including trichostatin A (TSA) 17, 18 , valproic acid (VPA) 17, 19 , nifedipine (Nif) 20 , IGF1 [21] [22] [23] and IGF2
24
. We treated control and PMDS neurons over the course of 2 to 20 days and measured the number of HOMER1 1 SYN1 1 puncta. Only IGF1 increased the number of SYN1 1 HOMER1 1 puncta to the levels observed in control neurons in the same culture (Fig. 5a-b) . We also found that IGF1 increased the average amplitude and frequency of spontaneous EPSCs in PMDS neurons to control levels (Fig. 5c ), but had no effect on spontaneous IPSCs (Supplementary Fig. 12 ). IGF1 also restored the amplitude of evoked AMPA-and NMDA-EPSCs (Fig. 5d) and reduced the input resistance of PMDS neurons to that observed in control neurons ( Supplementary Fig. 13 ). Finally, IGF1 completely restored the whole-cell NMDA receptor currents evoked by focal application of NMDA, but failed to fully restore whole-cell AMPA receptor currents elicited by application of AMPA ( Supplementary Fig. 14) . Together, these results indicate that treatment with IGF1 restores synaptic transmission in PMDS neurons by increasing the number of synaptic AMPA and NMDA receptors.
To gain insight into the mechanism of IGF1 action, we measured SHANK3 expression in control and PMDS neurons treated with IGF1. Surprisingly, we found that IGF1 caused a marked decrease of SHANK3 protein expression in the cell body and processes of both control and PMDS neurons (Supplementary Fig. 15 ). We next examined SHANK3 expression at synapses by infecting cells with GFP-tagged SHANK3 and staining neurons with the postsynaptic antibody anti-PSD95 (Supplementary Fig. 16a ). We found only 50% overlap between SHANK3-and PSD95-containing puncta in human iPS cell-derived neurons. A similar pattern of SHANK3 and PSD95 expression was detected in the human fetal brain tissue immunostained with anti-SHANK3 and anti-PSD95 antibodies (Supplementary Fig. 16b ). This indicates that in developing neurons there are three populations of excitatory synapses: those that contain SHANK3 alone, those that contain SHANK3 and and decreased number of synapses. a, Quantification of expression of AMPA and NMDA receptors in control and PMDS neurons using western blot (day in vitro 45-50; n 5 3-11 pairs of samples; **P , 0.01, ***P , 0.001, one-sample t-test). GAPDH was used as a loading control. b, c, Representative currents (top) and peak current versus voltage curves (bottom) recorded in control and PMDS neurons in response to focal application of 200 mM AMPA (measured at a holding potential of270 to 150 mV, D20 mV, n 5 7 control and 11 PMDS cells) and 100 mM NMDA/10 mM Gly (260 to 160 mV, D20 mV, n 5 21 control and 30 PMDS cells). Data presented as means 6 s.e.m.; *P , 0.05, ***P , 0.001, Mann-Whitney test. d, Images of co-cultured control (green) and PMDS (red) neurons immunostained for mKate2, GFP, SYN1 and HOMER1. Scale bars, 20 (left) and 5 mm (right). e, f, Cumulative distributions of the number of SYN1
1 (e) and HOMER1 1 SYN1 1 (f) puncta on co-cultured control and PMDS neurons; *P , 0.05, ***P , 0.001, Kolmogorov-Smirnov test.
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PSD95, and those that contain PSD95 alone. We investigated the effect of IGF1 on these three populations of synapses by staining neurons with anti-SHANK3 and anti-PSD95 antibodies (Fig. 5e) . Treatment with IGF1 caused a decrease in the number of puncta expressing SHANK3 alone in control neurons, but had little effect in PMDS neurons, which already had reduced levels of SHANK3 (Fig. 5f ). In contrast, IGF1 caused a 45% and 340% increase in the fraction of puncta expressing PSD95 in control and PMDS neurons, respectively, while decreasing the number of puncta containing both markers (Fig. 5f ). To determine if synapses that lack SHANK3 are functionally different, we analysed the physiological properties of synapses in PMDS and control neurons. We found that PMDS neurons have a significantly faster rate of decay of NMDA-EPSCs relative to control cells and treatment with IGF1 increased the decay rate of NMDAEPSCs in control neurons to match the rate of decay in PMDS neurons (Fig. 5g) . In contrast, SHANK3 expression in PMDS neurons caused a decrease in the rate of decay of NMDA-EPSCs to match that in untreated control neurons (Fig. 5g) . These results are consistent with the idea that IGF1 treatment rescues synaptic transmission in PMDS neurons by causing loss of SHANK3-containing synapses and gain of PSD95-containing synapses, which are characterized by rapidly decaying NMDA-EPSCs (Fig. 5h) .
Here, we show that neurons derived from iPS cells from PMDS patients have major defects in excitatory synaptic transmission arising from both a failure to form the correct number of excitatory synapses and a reduction in the expression of glutamate receptors. As no significant impairments in inhibitory synaptic transmission were found, this resulted in an imbalance between excitation and inhibition at a cellular level. Only some aspects of the phenotype detected in human cells are similar to those found in mouse models of PMDS [25] [26] [27] . Why there is a discrepancy is unclear. One potentially important issue is that there are multiple SHANK3 isoforms. PMDS patients generally lack the entire gene on one chromosome, whereas mice typically lack only some of the isoforms and have generally been studied as homozygote knockouts. We also demonstrated that SHANK3 and IGF1 largely restore synaptic deficits in PMDS neurons. Interestingly, IGF1 decreases SHANK3 expression and promotes the formation of a class of synapses containing PSD95 but lacking SHANK3. One possibility is that SHANK3 is required at an early stage of synapse formation, and that IGF1 promotes maturation of synapses by triggering the loss of SHANK3 and recruitment of PSD95. Consistent with this view, SHANK3-containing synapses have slowly decaying NMDA receptor currents that resemble those of GLUN2B receptors that occur early in development, whereas synapses that contain PSD95 but lack SHANK3 have rapidly decaying NMDA receptor currents that resemble the GLUN2A-containing synapses that appear later in development 28 . In summary, we have identified synaptic defects in iPS cell-derived neurons from patients with PMDS and we show that these defects depend on loss of SHANK3 and can be reversed by IGF1.
METHODS SUMMARY
Primary fibroblasts from consenting patients with PMDS were acquired by skinpunch biopsy following approved SCRO and IRB protocols. iPS cell lines from the fibroblasts were generated using standard reprogramming techniques 11, 12 . iPS cells 
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were differentiated into neurons using a modified monolayer differentiation protocol ( Supplementary Fig. 3) . Properties of iPS cell-derived neurons were characterized using qRT-PCR, multiplex single-cell qRT-PCR, electrophysiology, immunocytochemistry and western blot. A detailed description of all the procedures, materials and methods used in this study is available in the Methods section. Performed experiments are also summarized in Supplementary Table 3 .
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Recruitment of patients with PMDS and skin biopsy procedure. Participants diagnosed with 22q13 deletion syndrome were recruited from on-going research studies, the medical genetics service at Lucile Packard Children's Hospital, and interest groups for patients and families with genetic disorders associated with autistic spectrum manifestations. Consenting participants were evaluated with the Autism Diagnostic Observation Schedule (ADOS) and, when possible, the Stanford-Binet Intelligence Scales, Fifth Edition (SB5). In addition, parents of participants completed the Autism Diagnostic Interview-Revised (ADI-R) and questionnaires about the participant, including a medical history questionnaire and the Social Responsiveness Scale (SRS). All assessors were trained nationally and certified as reliable in the administration of ADOS and ADI-R assessments. Skin punch biopsies were performed as follows: after local anaesthesia with topical and injected xylocaine, a shallow, 3-mm punch biopsy sample was obtained from either the forearm or thigh.
This study was approved by both the Stanford University Institutional Review Board (IRB) and the Stem Cell Research Oversight Committee (SCRO). Generation and characterization of iPS cell lines. Detailed procedures used for the generation, maintenance, and characterization of iPS cells were previously described 12 . Briefly, primary fibroblasts from patients with PMDS were acquired by skin-punch biopsy following approved SCRO and IRB protocols. Cells were propagated for 2-3 passages, plated at 100,000 cells per well in six-well plates, and infected with retroviruses carrying SOX2, OCT3/4, c-MYC and KLF4 transcription factors the next day. iPS cells colonies, normally detected 21-30 days after the first infection, were routinely maintained on irradiated CF1 feeder cells in iPS cell medium (DMEM/F12 (11330-032, Gibco), containing 20% Knockout SR (10828-028, Gibco), 1% MEM (11140, Gibco), 0.5% L-glutamine (25030, Gibco), 1% penicillin streptomycin (15140, Gibco), 0.1 mM b-mercaptoethanol (Sigma) and 10 ng ml 21 basic fibroblast growth factor (R&D Systems)). iPS cells were immunostained with antibodies against NANOG (AF1997, R&D Systems) and TRA-2-49/6E (developed by P. W. Andrews and obtained from the Development Studies Hybridoma Bank developed under the auspices of the National Institute of Child Health and Development (NICHD) and maintained in the University of Iowa, Department of Biological Sciences).
SKY analysis of all iPS cell lines was performed according to a standard procedure. Briefly, metaphases were extracted after overnight incubation in 0.03 mg ml 21 KaryoMAX Colcemid solution in iPS cell media. Chromosomes were isolated and stained with the SKYPaint probe mixture and CAD kit (Applied Spectral Imaging), following the manufacturer's protocol. Spreads were imaged on a Leica microscope (DM400B), equipped with SpectraCubeSD300 and a 363 objective, using Case Data Manager 6.0 and HiSKY 6.0 software (Applied Spectral Imaging). Twenty spreads from each iPS cell line with well-separated chromosomes were imaged and analysed for visible chromosome abnormalities.
For the teratoma formation assay, iPS cells from a confluent 10-cm dish were enzymatically collected, washed and resuspended in 1.5 ml of PBS. Cells were then injected into the kidney capsules of SCID mice (Charles River Laboratories International). Visible tumours were dissected 3-8 weeks post-transplantation and fixed in 4% paraformaldehyde. Fixed samples were sent to the Cureline Biopathology Laboratory for paraffin embedding, sectioning and staining with haematoxylin and eosin. Sections were then examined for the presence of tissue representatives of all three germ layers.
Genomic DNA from fibroblasts and iPS cells was isolated using the DNeasy Blood & Tissue kit (Qiagen). Haploinsufficiency of SHANK3 in fibroblasts and all iPS cells of patients, was verified using the SALSA MLPA kit (P188, MRC-Holland), following the manufacturer's protocol. Neural differentiation. For neural differentiation, a combination of two protocols was used 29, 30 . The rationale and detailed procedures are presented in Supplementary Fig. 3 . qRT-PCR. qRT-PCR was performed in a real-time thermal cycler (Mastercycler ep realplex, Eppendorf) using either FastStart Universal SYBR Green (Rox) (Roche) or RT qPCR master mixes (SABiosciences). Total RNA was isolated using the RNeasy Mini kit (Qiagen). cDNA was synthesized with either the SuperScript III First-Strand Synthesis kit (Invitrogen) or the RT First Strand kit (SABiosciences). All primers are listed in Supplementary Table 5 . Multiplex single-cell qRT-PCR. Single cells were collected either by aspiration with a patch glass pipette filled with 4 ml of sterile intracellular solution or by FACS sorting using a BD influx sorter (BD Biosciences) into 10 ml of a pre-amplification mix containing 40 nM of all primers for the genes of interest and the following components of the CellsDirect One-Step qRT-PCR kit (Invitrogen): 2 3 Reaction Mix, SuperScript III RT/Platinum Taq Mix. After collection, samples were reversetranscribed and pre-amplified for 18 cycles. Pre-amplified samples were diluted (3 3 ) with TE buffer and stored at 220 uC. Sample and assay (primer pairs) preparation for 96.96 Fluidigm Dynamic arrays was done according to the manufacturer's recommendation. Briefly, each sample was mixed with 20 3 DNA binding dye sample-loading reagent (Fluidigm), 20 3 EvaGreen (Biotium) and TaqMan Gene Expression master mix (Applied Biosystems). Assays were mixed with 2 3 assay loading reagent (Fluidigm) and TE to a final concentration of 5 mM. The 96.96 Fluidigm Dynamic Arrays (Fluidigm) were primed and loaded on an IFC Controller HX (Fluidigm) and quantitative PCR experiments were run on a Biomark System for Genetic Analysis (Fluidigm). Melting curves were used to determine the specificity of each reaction. In addition to single-cell material, every experiment contained four standard dilutions of a mixed human cDNA library. Data were collected and analysed using Fluidigm Real-Time PCR Analysis software (v.2.1.3 and v.3.0.2). Threshold cycle (CT) as a measure for original template amount was used for quantification. To compare the data acquired from different chips, the C t values were normalized to the median intensity of the entire chip. Because single-cell gene expression in mammals occurs in bursts and follows a binary distribution, we established 32 cycles (at least five standard deviations from the mean of the lowest expressed genes) as a general threshold for whether or not a gene is expressed. Electrophysiology. All recordings were performed at room temperature (22-25 uC) on GFP-or mKate2-expressing iPS cell-derived neurons on day 31-45 (separate cultures without astrocytes) or day 45-52 (co-cultured on rat cortical astrocytes). Briefly, neurons grown on cover slips or 35-mm plastic dishes were visualized with a 340 air objective on an inverted Nikon microscope (Ellipse TE2000) and recorded using an EPC10 amplifier (HEKA). The following solutions were used (in mM): extracellular, 140 NaCl, 2.5 KCl, 2. . Spontaneous EPSCs and IPSCs were recorded for 3 min (1 min after break-in to block sodium current by QX-314) at holding potential 270 mV. Recordings were filtered at 2 kHz and digitized at 4 kHz. Evoked postsynaptic currents were measured after spontaneous currents and induced by brief (1 ms) unipolar current pulses of various amplitudes (0.1-0.9 mA, D 5 0.05-0.1 mA), delivered with a stimulating electrode (CBAEC75, FHC) positioned 100-150 mm from the cell soma and connected to an external stimulator (A365, WPI). Recordings were filtered at 2 kHz and digitized at 10 kHz. NMDA-, AMPA-and c-aminobutyric acid-currents were induced by a focal transient application of the following agonists (in mM): 100 NMDA and 10 Gly, 200 AMPA, or 100 c-aminobutyric acid. An injection pipette (patch pipette with resistance of 1-2 MV when filled with extracellular solution) was positioned about 20 mm from the cell soma and connected to a pico-spritzer (PDES-02DX, npi Electronics) with 10 p.s.i. in-line pressure. In all experiments, access resistance was monitored throughout the experiment (,15 MV), but not compensated. Cells were included for analysis only if the change of resistance was ,25% throughout the experiment.
Data were collected and initially analysed with Patchmaster software (HEKA). Further analysis was performed using Clampfit 10 (Molecular Devices), IgorPRO (Wavemetrics), Excel (Microsoft) and Prism (GraphPad). The baseline noise amplitude in our experiments was about 2.5 pA. Spontaneous EPSCs were detected using a template search procedure in Clampfit 10. A template for automatic EPSC detection was created by averaging 50 manually picked synaptic events. Spontaneous IPSCs were detected using MiniAnalysis software. The decay kinetics of NMDA-EPSCs was estimated using a weighted decay time constant (t decay ) 31 , calculated from the area under the normalized current on an interval from 16.4 ms (3 3 t AMPA decay ) to 1.1 s after the peak of AMPA-EPSC. Western blot analysis. Cells grown in 2-cm dishes were lysed in a standard RIPA buffer containing a protease inhibitor cocktail (Roche Diagnostics). Protein concentrations were measured using a BCA protein assay kit (Thermo). Proteins were denatured with Laemmli buffer at 70 uC for 10 min, separated on a NuPAGE 4-12% Bis-Tris gel (Novex), and transferred to a polyvinylidene difluoride (PVDF) membrane. Membranes were blocked in 5% milk (1 h at room temperature) and blotted with the following primary antibodies (overnight at 4 uC): guinea pig anti-SHANK3 (1:700, gift from Carlo Sala), mouse anti-GLUN1 (1:1,000, SYSY), rabbit anti-GLUA1 (1:1,000, Upstate), mouse anti-GLUA2 (1:1,000, NeuroMab), and mouse anti-GAPDH (MS, 1:1,000, Ambion). To control loading protein amounts, we first quantified the relative concentrations of GAPDH in all lysates. Afterwards, RESEARCH LETTER
